This site is intended for Healthcare Professionals only.

DHSC releases second list of January price concessions


Share post:

The Department of Health and Socialcare (DHSC) today published its second list of price concessions for January 2020.

The announcement, revealed by the PSNC, follows the first announcement on January 15.

The latest list (below) covers 32 drugs.

Amiloride 5mg tablets 28 £22.38
Co-careldopa 25mg/100mg tablets 100 £10.69
Diclofenac sodium 75mg modified-release tablets 56 £15.00
Fluoxetine 10mg capsules 30 £47.50
Hydroxyzine 10mg tablets 84 £2.12
Hydroxyzine 25mg tablets 28 £1.09
Irbesartan 75mg tablets 28 £2.80
Irbesartan 300mg tablets 28 £5.53
Irbesartan 300mg / Hydrochlorothiazide 12.5mg tablets 28 £4.99
Lamotrigine 25mg dispersible tablets sugar free 56 £9.71
Levetiracetam 250mg tablets 60 £3.60
Lymecycline 408mg capsules 28 £5.70
Meloxicam 7.5mg tablets 30 £2.80
Meloxicam 15mg tablets 30 £5.60
Memantine 10mg tablets 28 £3.20
Memantine 20mg tablets 28 £8.05
Mirtazapine 15mg tablets 28 £2.10
Mirtazapine 30mg tablets 28 £2.20
Mirtazapine 45mg tablets 28 £2.40
Nefopam 30mg tablets 90 £14.96
Nitrazepam 5mg tablets 28 £2.70
Nitrofurantoin 50mg tablets 28 £13.27
Nitrofurantoin 100mg tablets 28 £9.32
Oxytetracycline 250mg tablets 28 £4.93
Ranitidine 300mg tablets 30 £4.80
Rivastigmine 3mg capsules 28 £4.29
Sulpiride 200mg tablets 30 £6.48
Tolterodine 2mg tablets 56 £2.62
Trihexyphenidyl 2mg tablets 84 £7.95
Venlafaxine 37.5mg tablets 56 £7.90
Venlafaxine 75mg tablets 56 £14.50


Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

ABPI: Increased pharma exports could boost GDP by £16.3 billion

ABPI urges political leaders to enhance healthcare and economic growth through strategic partnership The Association of the British Pharmaceutical...

The Importance Of Expanding Access To Dental Care For Rural And Undeserved Populations

In many rural areas and underserved neighborhoods, a critical issue is quietly emerging. Although often overlooked, its effects...

BGMA: More than 50% of UK generics face shortages without licensed alternatives

Brexit blamed by BGMA CE, Mark Samuels, as UK faces critical shortages in generic drug supply A recent report...

Paul Burden elected BGMA Vice-Chair, bringing 25 years of industry leadership

Veteran of off-patent sector to drive strategic engagement and patient access initiatives at BGMA The British Generic Manufacturers Association...